Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Drugs
981-1,000 of 1,325 results
-
-
Podcast: KHN’s ‘What The Health?’ ACA Under Fire. Again.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the health politics of the latest Supreme Court pick, as well as the Trump administration’s efforts to further undermine the Affordable Care Act. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
-
Can Insurers Use Genetic Testing Results? A Reader Wants To Know
Other readers ask what can be done to challenge unexpected medical bills — whether the result of an emergency room visit or after a change in prescription drug coverage.
-
State Prisons Fail To Offer Cure To 144,000 Inmates With Deadly Hepatitis C
A survey of 49 states reveals that an estimated 144,000 inmates with hepatitis C, a curable but potentially fatal disease, can’t get the expensive drugs they need to cure it.
-
Podcast: KHN’s ‘What The Health?’ Whither Work Requirements?
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Anna Edney of Bloomberg News discuss the latest enrollment numbers for the Affordable Care Act, Medicaid work requirements in Kentucky and President Donald Trump’s proposed government reorganization plan. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
-
Tennessee-Based Pain Management Group To Close Clinics Amid Financial Turmoil
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
By Fred Schulte -
Out-Of-Pocket Costs Put HIV Prevention Drug Out Of Reach For Many At Risk
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.
By Shefali Luthra and Anna Gorman -
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
-
Doling Out Pain Pills Post-Surgery: An Ingrown Toenail Not The Same As A Bypass
As the opioid epidemic rages, a Johns Hopkins surgeon and researcher is leading an effort to curb overprescribing by offering procedure-specific guidelines to ensure that post-surgical patients leave the hospital with enough, but not too much, pain medication.
-
Purdue And The OxyContin Files
Purdue Pharma planned an extensive marketing campaign for the launch and promotion of the painkiller OxyContin. Here are Purdue’s internal budget documents from 1996 to 2002 — files released by the Florida attorney general’s office — that detail the company’s early strategy to sell and expand use of the drug.
-
KHN EXCLUSIVE
How America Got Hooked On A Deadly Drug
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
By Fred Schulte -
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Looking For Lower Medicare Drug Costs? Ask Your Pharmacist For The Cash Price.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
By Susan Jaffe -
Benefit Change Could Raise Costs For Patients Getting Drug Copay Assistance
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
-
Best Reads Of The Week With Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ Campaign Promises Kept, Plus ‘Nerd Reports’
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Sarah Kliff of Vox and Alice Ollstein of Talking Points Memo discuss a proposed administration regulation that seeks to separate Planned Parenthood from federal family planning funds, the final congressional passage of legislation aimed at helping those with terminal illnesses obtain experimental medications, and new government reports on the uninsured and federal health spending. Also, Rovner interviews KHN’s Liz Szabo about the May “Bill of the Month.”
-
Pfizer Settles Kickback Case Related To Copay Assistance For $24M
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
-
Watch: What’s In The White House Plan To Lower Drug Prices
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ "Red & Blue."